Adaptimmune Therapeutics Plc - ADR
ADAP
Get informed when a big investor buys or sells
+ FollowMarket Cap$12.81M
Close$
$2.33
4709.1% upside
Current Fair Value
4709.1% upsideUndervalued by 4709.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $12.81 Million |
|---|---|
| Enterprise Value | $50.64 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.28 |
| Beta | 2.49 |
| Outstanding Shares | 264,087,145 |
Return
| Return on Equity | 239.23% |
|---|---|
| Return on Assets | -129.95% |
| Return on Invested Capital | -202.67% |
Valuation & Multiples
| P/E Ratio | -0.11 |
|---|---|
| PEG | 0.07 |
| Price to Sales | - |
| Price to Book Ratio | -0.05 |
| Enterprise Value to Revenue | 0.78 |
| Enterprise Value to EBIT | -0.32 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 1.26 |
| Debt to Equity | -0.9 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
November 12, 2025
EPS Estimate
$-0.09
Average shareholder expectationRevenue Estimate
$11.28 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 103.53% |
|---|---|
| Total Calls | 907▼ 99.35% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.62%▼ 15.32% |
|---|---|
| Total Invested | $79,697▼ 98.54% |
| Investors Holding | 8▼ 49.00% |
ESG Score
No data
About Adaptimmune Therapeutics Plc
272 employees
CEO: Christopher James Hill Adaptimmune Therapeutics plc is a commercial-stage biopharmaceutical company specializing in innovative cell therapies for cancer patients, primarily operating in the United States and the United Kingdom. Its pipeline includes TECELRA (a...